-
EP4472679
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4472679
| EP4472679 - REGIONAL TAU IMAGING FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 08.11.2024 Database last updated on 08.04.2026 | |
| Former | The international publication has been made Status updated on 11.08.2023 | ||
| Former | unknown Status updated on 18.04.2023 | Most recent event Tooltip | 04.02.2026 | New entry: Renewal fee paid | Applicant(s) | For all designated states Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2024/50] | Inventor(s) | 01 /
KOTARI, Vikas Indianapolis, Indiana 46206-6288 / US | 02 /
SHCHERBININ, Sergey Indianapolis, Indiana 46206-6288 / US | 03 /
SOUTHEKAL, Sudeepti Suresh Indianapolis, Indiana 46206-6288 / US | 04 /
TUNALI, Ilke Indianapolis, Indiana 46206-6288 / US | [2024/50] | Representative(s) | Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [N/P] |
| Former [2024/50] | Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell Berkshire RG12 1PU / GB | Application number, filing date | 23716079.1 | 30.01.2023 | [2024/50] | WO2023US61544 | Priority number, date | US202263306168P | 03.02.2022 Original published format: US 202263306168 P | US202263369795P | 29.07.2022 Original published format: US 202263369795 P | US202263382914P | 09.11.2022 Original published format: US 202263382914 P | [2024/50] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2023150483 | Date: | 10.08.2023 | Language: | EN | [2023/32] | Type: | A1 Application with search report | No.: | EP4472679 | Date: | 11.12.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.08.2023 takes the place of the publication of the European patent application. | [2024/50] | Search report(s) | International search report - published on: | EP | 10.08.2023 | Classification | IPC: | A61K51/04, C07K16/18, A61P25/00, A61K39/00 | [2024/50] | CPC: |
A61K51/0455 (EP,IL,KR);
A61B6/501 (US);
A61B6/037 (US);
A61B6/5217 (US);
A61P25/00 (EP,IL);
A61P25/28 (KR);
C07K16/18 (EP,IL,KR);
G01N33/6896 (EP,IL,KR);
A61K2039/505 (EP,IL,KR);
A61K2039/55 (EP,IL,KR);
G01N2333/4709 (EP,IL,KR);
G01N2800/2821 (EP,IL,KR);
G01N2800/52 (EP,IL,KR)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/50] | Extension states | BA | 03.09.2024 | Validation states | MA | 03.09.2024 | MD | 03.09.2024 | TN | 03.09.2024 | Title | German: | REGIONALE TAU-BILDGEBUNG ZUR DIAGNOSE UND BEHANDLUNG VON MORBUS ALZHEIMER | [2024/50] | English: | REGIONAL TAU IMAGING FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE | [2024/50] | French: | IMAGERIE DE TAU RÉGIONALE POUR LE DIAGNOSTIC ET LE TRAITEMENT DE LA MALADIE D'ALZHEIMER | [2024/50] | Entry into regional phase | 03.09.2024 | National basic fee paid | 03.09.2024 | Designation fee(s) paid | 03.09.2024 | Examination fee paid | Examination procedure | 02.09.2024 | Amendment by applicant (claims and/or description) | 03.09.2024 | Examination requested [2024/50] | 03.09.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 31.01.2025 | Renewal fee patent year 03 | 02.02.2026 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X] WO2020243346 (MASSACHUSETTS GEN HOSPITAL et al.) | [XY] WO2017083198 (LILLY CO ELI et al.) | [Y] WO2018005282 (LILLY CO ELI et al.) | [Y] US2021284720 (KERCHNER GEOFFREY et al.) | [Y] WO2014182631 (BAXTER INT et al.) | [XP] WO2022192636 (LILLY CO ELI et al.) | [XP] WO2022192639 (LILLY CO ELI et al.) | [XP] WO2022150735 (LILLY CO ELI et al.) | [E] WO2023076995 (LILLY CO ELI et al.) | [X] MINTUN MARK A. ET AL: "Donanemab in Early Alzheimer's Disease", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 384, no. 18, 6 May 2021 (2021-05-06), pages 1691 - 1704, XP055910565, ISSN: 0028-4793, DOI: 10.1056/NEJMoa2100708 DOI: http://dx.doi.org/10.1056/NEJMoa2100708 | [X] SHCHERBININ SERGEY ET AL: "OC15 - Flortaucipir in the trailblazer-ALZ trial", JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE, vol. 8, no. Suppl.1, 9 November 2021 (2021-11-09), pages S22 - S23, XP093058240, ISSN: 2426-0266, DOI: 10.14283/jpad.2021.57 DOI: http://dx.doi.org/10.14283/jpad.2021.57 | [XDY] PONTECORVO MICHAEL J. ET AL: "Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition", BRAIN, vol. 140, no. Part 3, 11 January 2017 (2017-01-11), pages 748 - 763, XP093057211, ISSN: 0006-8950, DOI: 10.1093/brain/aww334 DOI: http://dx.doi.org/10.1093/brain/aww334 | [XDY] SOUTHEKAL SUDEEPTI ET AL: "Flortaucipir F18 Quantitation Using Parametric Estimation of Reference Signal Intensity", THE JOURNAL OF NUCLEAR MEDICINE, vol. 59, no. 6, 1 June 2018 (2018-06-01), pages 944 - 951, XP093057203, ISSN: 0161-5505, Retrieved from the Internet DOI: http://dx.doi.org/10.2967/jnumed.117.200006 | [XDY] PONTECORVO MICHAEL J ET AL: "A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia", BRAIN, vol. 142, no. 6, 1 June 2019 (2019-06-01), pages 1723 - 1735, XP093057199, ISSN: 0006-8950, Retrieved from the Internet DOI: http://dx.doi.org/10.1093/brain/awz090 | [XY] SCHWARZ ADAM J: "The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders", NEUROTHERAPEUTICS, vol. 18, no. 2, 1 April 2021 (2021-04-01), pages 686 - 708, XP037557905, ISSN: 1933-7213, [retrieved on 20210412], DOI: 10.1007/S13311-021-01027-4 DOI: http://dx.doi.org/10.1007/s13311-021-01027-4 | [XY] SIDEROWF ANDREW D ET AL: "COMPARISON OF REGIONAL FLORTAUCIPIR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER'S DISEASE PATHOLOGY: A PILOT CLINICO-PATHOLOGICAL STUDY", ALZHEIMER'S & DEMENTIA, vol. 13, no. 7, 17 July 2017 (2017-07-17), XP085216814, ISSN: 1552-5260, DOI: 10.1016/J.JALZ.2017.06.1038 DOI: http://dx.doi.org/10.1016/j.jalz.2017.06.1038 | [XY] FLEISHER A S ET AL: "Tau pet imaging as a screening tool for clinical trials of disease modifying therapies", JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE, vol. 5, no. 1, OC12, 1 October 2018 (2018-10-01), & 11th Conference Clinical Trials Alzheimer's Disease, 24-27 October 2018, Barcelona, ES, pages S17 - S18, XP009545026, ISSN: 2426-0266, DOI: 10.14283/jpad.2018.39 DOI: http://dx.doi.org/10.14283/jpad.2018.39 | [Y] LOWE S ET AL: "Treatment with donanemab, A B-amyloid plaque-specific antibody, results in rapid and sustained reduction of amyloid measured by F-18 florbetapir imaging in Alzheimer's disease", JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE, vol. 6, no. Supplement 1, 1 December 2019 (2019-12-01), & 12th Conference Clinical Trials Alzheimer's Disease, 20191204 to 20191207, San Diego, US, 4-7 December 2019, pages S8, XP009544994, ISSN: 2426-0266, [retrieved on 20191208], DOI: 10.14283/JPAD.2019.47 DOI: http://dx.doi.org/10.14283/jpad.2019.47 | [Y] JEFF SEVIGNY ET AL: "The antibody aducanumab reduces A&bgr; plaques in Alzheimer’s disease", NATURE, vol. 537, no. 7618, 31 August 2016 (2016-08-31), pages 50 - 56, XP055394640, ISSN: 0028-0836, DOI: 10.1038/nature19323 DOI: http://dx.doi.org/10.1038/nature19323 | [Y] HONIG LAWRENCE S. ET AL: "Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 378, no. 4, 25 January 2018 (2018-01-25), pages 321 - 330, XP055954469, ISSN: 0028-4793, Retrieved from the Internet DOI: http://dx.doi.org/10.1056/NEJMoa1705971 | by applicant | US8679498 | US8961972 | US2017038999 | US10647759 | US11078261 | US7195761 | US2006039906 | US7892545 | US8591894 | US7771722 | US2007190046 | US10081625 | WO2022020663 | VILLEMAGNE ET AL., ANN NEUROL, vol. 69, 2011, pages 181 - 192 | PONTECORVO ET AL.: "A Multicentre Longitudinal Study of Flortaucipir (18F) in Normal Ageing, Mild Cognitive Impairment and Alzheimer's disease Dementia", BRAIN, vol. 142, 2019, pages 1723 - 35 | DEVOUS ET AL.: "Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F18", JOURNAL OF NUCLEAR MEDICINE, vol. 59, 2018, pages 937 - 43 | SOUTHEKAL ET AL.: "Flortaucipir F18 Quantitation Using Parametric Estimation of Reference Signal Intensity", J. NUCL. MED., vol. 59, 2018, pages 944 - 951 | FLEISHER ET AL.: "Positron Emission Tomography Imaging With F18-flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes", JAMA NEUROLOGY, vol. 77, 2020, pages 829 - 39 | PONTECORVO ET AL.: "Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition", BRAIN, 2017, pages 1 - 16 | DEVOUS ET AL.: "Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F18", J. NUCL. MED., vol. 59, 2018, pages 937 - 943 | BAO ET AL., AGING NEUROSCI, vol. 13, 2021, pages 624330 | TZOURIO-MAZOYER ET AL., NEUROIMAGE, vol. 15, 2002, pages 273 - 289 | OSSENKOPPELE ET AL., JAMA NEUROLOGY, 2021 | PONTECORVO ET AL., BRAIN, 2019 | SOUTHEKAL ET AL., JOURNAL OF NUCLEAR MEDICINE, 2018 |